Industry Alliance Program – Highlighted CIRM-Catalyzed Spinouts
CIRM’s support has been instrumental to our early successes and our ability to rapidly progress Forty Seven’s CD47 antibody targeting approach with magrolimab. CIRM was an early collaborator in our clinical programs and it’s support was instrumental in helping us reach a point where we could become a part of Gilead and move forward with our research.”
Highlighted CIRM-Catalyzed Spinouts
CIRM funding to California academic institutions has enabled the launch of more than 40
spinout companies, some of which are highlighted below.
Partner with CIRM to accelerate stem cell, gene and
regenerative medicine therapies.